WebMD

Alhemo: A New Daily Injection to Help Prevent Bleeding in Hemophilia A and B

What Is Alhemo, and Why Does It Matter? Alhemo (concizumab-mtci) is a medicine approved to help prevent bleeding in people aged 12 or older with hemophilia A or B who don’t have inhibitors to certain ...
Seeking Alpha

Novo Nordisk bleeding prevention injection for hemophilia granted FDA nod

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders, ...
Monthly Prescribing Reference

Alhemo Approved for Treatment of Hemophilia A or B With Inhibitors

Findings showed concizumab-treated patients had an 86% reduction in annualized bleeding rate compared with no prophylaxis. The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci ...
Medscape

FDA Approves Pfizer's Hympavzi for Hemophilia A, B

The US Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older who ...

Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) stock is in focus as the firm gets FDA priority review for its marketing application seeking a label expansion ...
KXAN

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved

SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by ...
Mirage News

FDA Fast-Tracks HYMPAVZI for Hemophilia & B Treatment

Pfizer Inc. (NYSE: PFE)today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's ...
MedPage Today

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents ages 12 years and older with hemophilia A without factor VIII ...
Benzinga.com

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding ...
Healio

FDA approves Hympavzi for hemophilia A or B without inhibitors

Please provide your email address to receive an email when new articles are posted on . The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia. The indication applies ...
WebMD

What to Know About Esperoct for Hemophilia A

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...
MarketWatch

Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for the ...